uniQure (NASDAQ:QURE) PT Raised to $10.00 at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its price target raised by The Goldman Sachs Group from $6.00 to $10.00 in a report published on Friday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on QURE. HC Wainwright reissued a buy rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday, July 9th. Cantor Fitzgerald reissued an overweight rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, July 16th. Finally, Mizuho cut their target price on shares of uniQure from $7.00 to $6.00 and set a neutral rating on the stock in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $18.60.

uniQure Stock Performance

Shares of QURE stock opened at $7.58 on Friday. The company’s fifty day simple moving average is $6.02 and its 200-day simple moving average is $5.53. uniQure has a 52 week low of $3.73 and a 52 week high of $11.35. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70. The company has a market cap of $368.01 million, a PE ratio of -1.22 and a beta of 0.97.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative net margin of 1,027.52% and a negative return on equity of 137.05%. The business had revenue of $8.49 million during the quarter, compared to analysts’ expectations of $2.58 million. As a group, equities research analysts anticipate that uniQure will post -4.4 EPS for the current year.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sectoral Asset Management Inc. acquired a new position in uniQure during the 4th quarter worth $1,981,000. Bridger Management LLC boosted its holdings in shares of uniQure by 2,917.3% in the 4th quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock valued at $2,453,000 after buying an additional 350,340 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of uniQure by 133.1% in the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of uniQure by 458.5% in the 4th quarter. Vontobel Holding Ltd. now owns 295,042 shares of the biotechnology company’s stock valued at $1,997,000 after buying an additional 242,214 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of uniQure by 74.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after buying an additional 66,958 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.